Confirmatory Trial Trouble In KRAS (undefined:AMGN)

News Room
By News Room 7 Min Read

I wrote last year about KRAS-targeting drugs as cancer therapies, and that pretty much means G12C-KRAS targeting ones. That’s because years of effort had yielded no solid candidates for inhibiting “plain” KRAS in tumors, but a great deal of hard work has paid

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *